Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial

摘要

Background: Digoxin is recommended in symptomatic heart failure patients with reduced ejection fraction (HI -REF) in sinus rhythm and refractory to other evidence-based therapy. Although HI -REF patients with diabetes have worse functional status than those without, the effects of digoxin have not been specifically evaluated according to diabetes status.